Abstract
The paradigm of empiric treatment for advanced or metastatic non-small cell carcinoma of the lung (A-NSCLC) has been challenged in recent years, with an increasing emphasis on personalizing current therapies and utilizing new therapies that target the drivers of carcinogenesis. As more systemic therapies become available, decisions regarding the optimal type of therapy, timing and duration of treatment are becoming increasingly complex. Clinicians involved in the care of patients with lung cancer may wish to be kept up-to-date regarding the current approaches to treatment. Herein we provide an overview of the current systemic therapies for A-NSCLC, discussing evidence-based approaches to firstline, second-line and maintenance treatment. An outline of the pharmacology of the major classes of active drugs is given, and key evidence is outlined and organized by line of treatment. The characteristics of the target populations for treatment are discussed, along with the optimal combination and timing of therapy.
Keywords: Chemotherapy, bevacizumab, EGFR inhibitors, metastatic, pemetrexed, pharmacology, review, non-small cell carcinoma
Current Respiratory Medicine Reviews
Title: An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Volume: 7 Issue: 5
Author(s): Michael Ong and Mark D. Vincent
Affiliation:
Keywords: Chemotherapy, bevacizumab, EGFR inhibitors, metastatic, pemetrexed, pharmacology, review, non-small cell carcinoma
Abstract: The paradigm of empiric treatment for advanced or metastatic non-small cell carcinoma of the lung (A-NSCLC) has been challenged in recent years, with an increasing emphasis on personalizing current therapies and utilizing new therapies that target the drivers of carcinogenesis. As more systemic therapies become available, decisions regarding the optimal type of therapy, timing and duration of treatment are becoming increasingly complex. Clinicians involved in the care of patients with lung cancer may wish to be kept up-to-date regarding the current approaches to treatment. Herein we provide an overview of the current systemic therapies for A-NSCLC, discussing evidence-based approaches to firstline, second-line and maintenance treatment. An outline of the pharmacology of the major classes of active drugs is given, and key evidence is outlined and organized by line of treatment. The characteristics of the target populations for treatment are discussed, along with the optimal combination and timing of therapy.
Export Options
About this article
Cite this article as:
Ong Michael and D. Vincent Mark, An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189759
DOI https://dx.doi.org/10.2174/157339811797189759 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets Cell Compatibility of an Eposimal Vector Mediated by the Characteristic Motifs of Matrix Attachment Regions
Current Gene Therapy Direct Inhibitors of Ras-Effector Protein Interactions
Mini-Reviews in Medicinal Chemistry Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers
Anti-Cancer Agents in Medicinal Chemistry Treatment of Nasopharyngeal Carcinoma: Therapeutic Management and Future View of Epstein-Barr Virus-Targeting Treatment
Current Cancer Therapy Reviews Histone Methylation and microRNA-dependent Regulation of Epigenetic Activities in Neural Progenitor Self-Renewal and Differentiation
Current Topics in Medicinal Chemistry Fragment-Based Discovery of Inhibitors of Protein Kinase B
Current Topics in Medicinal Chemistry Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
Current Cancer Therapy Reviews Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Regulatory T Cells and Skin Tumors
Recent Patents on Inflammation & Allergy Drug Discovery